Impact of high loading-dose atorvastatin pre-treatment before primary percutaneous coronary intervention on coronary flow in patients with ST segment elevation myocardial infarction

ZHENG Bo,WANG Xin-gang,GONG Yan-jun,LI Jian-ping,CHEN Ming,HUO Yong,HONG Tao

DOI: https://doi.org/10.3969/j.issn.1004-8812.2013.01.011

2013-01-01

Abstract:Objective This study sought to investgate the impact of high loading-dose atorvastatin pre-treatment in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) on coronary reperfusion, short-term clinical outcome and safety.Methods We collected consecutive patients with STEMI in our hospital from January 2010 to March 2011,83 patients who did not receive any statin therapy before admission and only received atorvastatin after admission were included. Patients were divided in 2 groups :those who received atorvastatin 80 mg before primary PCI (n=41) and those who did not (n=42).The primary end point included thrombolysis in myocardial infarction flow grade, corrected thrombolysis in myocardial infarction frame count, and myocardial blush grade after PCI. Secondary end point was 30-day incidence of MACE including cardiovascular death, nonfatal MI, and target vessel revascularization. The safety end point was the level of liver enzyme, creatine kinase and serum creatinine.Results Baseline clinical and procedural characteristics were similar between the 2 groups. The proportion of thrombolysis in myocardial infarction flow grade 3 was higher in the 80-mg atorvastatin arm(87.8% vs. 64.3%,χ2=6.28,P=0.02), and corrected thrombolysis in myocardial infarction frame count was also lower in the 80-mg atorvastatin arm (21.72±9.42 vs. 32.64±15.51, t=-3.87,P<0.001). Simultaneously, myocardial blush grade were higher in the 80 mg atorvastatin arm (2.71±0.64 vs.2.15±0.74,t=3.68,P<0.001). MACE occurred in 2 (4.9%) and 2 (4.8%) patients in the atorvastain 80 mg pre-treatment and control arm, respectively (χ2=0.001,P=0.926).There was not significant difference of liver enzyme, creatine kinase and serum creatinine between 2 groups. Multivariate analysis showed that high loading-dose atorvastatin pre-treatment was associated with an odds ratio of 0.22 (95% confidence interval 0.06 to 0.87, P=0.03) for slow reflow or no reflow after PCI.Conclusions High loading-dose atorvastatin pre-treatment may produce an optimal result for STEMI patients undergoing PCI by improving microvascular myocardial perfusion without increasing the risk of side-effect.